Application of ibn-a new diabetes drug in Changshan pharmaceutical

The first class 1 new drug in Changshan pharmaceutical industry has been successfully applied for phase I clinical application and accepted in China, which marks the first step for the company to break through the heparin series products and lay out the diabetes field Changshan pharmaceutical announced last night that the company's registration application for class 1 diabetes long-acting drugs "ibuprofen natriuretic peptide" and "ibuprofen natriuretic peptide injection", which are highly concerned by the market, has been accepted by the State Food and drug administration It is understood that the application is for phase I clinical treatment in China At present, ibuprofen and its preparations have not been marketed at home and abroad Ibn is an intestinal hypoglycemic analog developed by Changshan kaijiejian, a joint venture of Changshan pharmaceutical and conguchem LLC in 2012, for the treatment of type 2 diabetes At present, the product has completed phase I and phase II clinical trials in the United States and Canada According to the research data, ibn-a-peptide has the advantages of long half-life, good clinical tolerance, once a week administration and definite effect Data shows that at present, the number of diabetes patients in China is more than 90 million, the potential diabetes patients are about 40 million, the domestic market scale of antidiabetic drugs is more than 10 billion yuan, and the annual growth rate is more than 10% Changshan pharmaceutical previously said that in view of the increasing number of diabetes patients in China and the increasing demand for antidiabetic drugs in the market, the company will obtain huge economic benefits after its listing In addition to the positive benefits, the success of Ibn will reduce the risk of excessive dependence on heparin products Changshan Pharmaceutical Co., Ltd is mainly engaged in heparin series products There are only two kinds of heparin preparations: low molecular weight heparin calcium injection and heparin sodium injection The company's performance is easily affected by the price fluctuation of API and preparation products It is reported that in addition to a variety of heparin products and ibuprofen, Changshan Pharmaceutical Co., Ltd is also developing new products including long-term anti-tumor targeting drugs According to the company's 2013 half year report, in the future, the company will gradually form a new strategic development layout with heparin series products as the core and diabetes and cancer drugs as the two wings Hebei Changshan Biochemical Pharmaceutical Co., Ltd., formerly known as Hebei Changshan Biochemical Pharmaceutical Co., Ltd., was founded on September 28, 2000 Since its establishment, the company has been committed to the research and development, production and sales of heparin products After years of development, it has gradually established a leading position in the field of heparin APIs and heparin preparations in China.